The earnings call reflects a positive outlook with strong performance in both late-stage and early-stage portfolios, record ARIKAYCE revenue, and successful capital raising, despite some concerns about the launch of brensocatib and uncertainties in certain trials.

Company Guidance -

Q3 2025

During Insmed's second quarter 2025 financial results conference call, the company provided guidance highlighting the continued success and growth potential of its key assets: ARIKAYCE, brensocatib, and TPIP. ARIKAYCE demonstrated consistent year-over-year growth in its seventh year, with expectations to meet the full year 2025 sales guidance driven by U.S., Europe, and Japan markets. The company anticipates the clinical readout of the Phase III ENCORE study in early 2026, potentially expanding ARIKAYCE's market by 225,000 patients. Brensocatib is on the verge of a significant U.S. launch, with European and Japanese launches expected in 2026. Insmed also foresees top line data from the BiRCh study by the end of 2025 and an interim futility analysis for the CEDAR study in early 2026. TPIP has shown positive Phase II results, with Phase III for PH-ILD planned for 2025 and PAH for early 2026. The company emphasized its robust financial position with $1.9 billion in cash, following a successful equity offering that raised approximately $823 million. Insmed is positioned to capitalize on its pipeline advancements and anticipates multiple clinical and commercial milestones over the next year.

Strong Late-Stage Portfolio Performance

Insmed's late-stage assets, ARIKAYCE, brensocatib, and TPIP, have shown positive Phase II or Phase III clinical data, marking a significant achievement.

Record ARIKAYCE Revenue

ARIKAYCE achieved the highest quarterly revenue ever in the United States, with significant growth in Japan (45%) and Europe (48%), driven by strong volume trends.

Successful Capital Raise

The company raised approximately $823 million in net proceeds from an equity offering, resulting in approximately $1.9 billion in cash, cash equivalents, and marketable securities.

Positive TPIP Phase IIb Trial Results

TPIP showed a 35% placebo-adjusted reduction in PVR and a 35.5-meter placebo-adjusted improvement in 6-minute walk distance in PAH patients.

Robust Early-Stage Portfolio Development

Insmed has over 30 preclinical programs in active development and has initiated its first Phase I study in patients with DMD.

Insmed (INSM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INSM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-1.36 / -	-1.27	―	―	―
Aug 07, 2025	2025 (Q2)	-1.29 / -1.70	-1.94	12.37% (+0.24)
May 08, 2025	2025 (Q1)	-1.34 / -1.42	-1.06	-33.96% (-0.36)
Feb 20, 2025	2024 (Q4)	-1.17 / -1.32	-1.28	-3.13% (-0.04)	―
Oct 31, 2024	2024 (Q3)	-1.20 / -1.27	-1.11	-14.41% (-0.16)	―
Aug 08, 2024	2024 (Q2)	-1.24 / -1.94	-1.78	-8.99% (-0.16)	―
May 09, 2024	2024 (Q1)	-1.24 / -1.06	-1.17	9.40% (+0.11)
Feb 22, 2024	2023 (Q4)	-1.15 / -1.28	-1.21	-5.79% (-0.07)
Oct 26, 2023	2023 (Q3)	-1.14 / -1.11	-1.09	-1.83% (-0.02)	―
Aug 03, 2023	2023 (Q2)	-1.13 / -1.78	-0.8	-122.50% (-0.98)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INSM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$111.26	$109.30	-1.76%
May 08, 2025	$68.28	$65.63	-3.88%
Feb 20, 2025	$83.83	$83.61	-0.26%
Oct 31, 2024	$70.30	$67.28	-4.30%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Insmed (INSM) report earnings?

Insmed (INSM) is schdueled to report earning on Oct 23, 2025, TBA (Confirmed).

What is Insmed (INSM) earnings time?

Insmed (INSM) earnings time is at Oct 23, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INSM EPS forecast?

INSM EPS forecast for the fiscal quarter 2025 (Q3) is -1.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing